Table 4.
C26/IL-12 Tumor–associated Vessels Detected by Immunocytochemistry
| CD31 | CD34 | αvβ3 | ||||
|---|---|---|---|---|---|---|
| BALB/c | 5 ± 4* | 4 ± 4 | ND | |||
| + mAb to CD8 | 41 ± 11 | 33 ± 8 | 5 ± 2 (12%)‡ | |||
| + mAb to CD4 | 3 ± 2 | 5 ± 2 | ND | |||
| GKO | 20 ± 6 | 21 ± 15 | <1 | |||
| + mAb to CD8 | 42 ± 13 | 31 ± 3 | <1 | |||
| + mAb to CD4 | 69 ± 26 | 51 ± 18 | 9 ± 2 (13%) | |||
| C26 in BALB/c | 71 ± 10 | 53 ± 15 | 9 ± 3 (13%) | |||
| C26 in GKO | 55 ± 16 | 31 ± 2 | 8 ± 2 (14%) |
Frozen sections were stained with mAb by immunocytochemistry (PAP method) except for αvβ3, which required a fluorescein-conjugated Ab followed by antifluorescein for detection by peroxidase. Tumors were analyzed at day 10.
*
Mean number of cells/mm2 ± SD positive for immunostaining.
‡
Percentage of CD31+ cells that were αvβ3 +.